Company: CRL
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001100682-25-000043
Chunk: 33

Company: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Filing Date: 2025-11-05
Form: 10-Q
Item: Item 2
Chunk 33
---
10 bps from 20.6% for the corresponding period in 2024. Operating income and operating income as a percentage of revenue decreased primarily due to the lower revenue described above, partially offset by lower severance costs, compared to the corresponding period in 2024.

Manufacturing

Three Months EndedSeptember 27, 2025September 28, 2024$ change% changeImpact of FX(in thousands, except percentages)Revenue$190,693 $196,879 $(6,186)(3.1)%2.0 %Cost of revenue (excluding amortization of intangible assets)109,944 113,152 (3,208)(2.8)%Selling, general and administrative32,556 32,737 (181)(0.6)%Amortization of intangible assets8,267 10,802 (2,535)(23.5)%Operating income$39,926 $40,188 $(262)(0.7)%2.7%Operating income % of revenue20.9 %20.4 %50 bps

Manufacturing revenue decreased $6.2 million primarily due to decreased revenue in our Biologics Solutions business, driven by decreased demand for CDMO and Biologics Testing services; partially offset by increased revenue in our Microbial Solutions business driven by higher product revenue associated with endotoxin product revenue and identification services revenue and the effect of foreign currency exchange rates.

Manufacturing operating income decreased $0.3 million during the three months ended September 27, 2025 compared to the corresponding period in 2024. Manufacturing operating income as a percentage of revenue for the three months ended September 27, 2025 was 20.9%, an increase of 50 bps from 20.4% for the corresponding period in 2024. Operating income decreased primarily due the lower revenue described above; partially offset by lower amortization related to acquisitions and severance charges compared to the corresponding period in 2024. Operating income as a percentage of revenue increased primarily due to lower severance charges and amortization related to acquisitions compared to the corresponding period in 2024.

30 

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Unallocated Corporate

Three Months EndedSeptember 27, 2025September 28, 2024$ change% changeImpact of FX(in thousands, except percentages)Unallocated corporate$63,833 $76,763 $(12